1.Epidemiological Surveillance:Genetic Diversity of Rotavirus Group A in the Pearl River Delta,Guangdong,China in 2019
Ying Jie JIANG ; Dan LIANG ; Li WANG ; Yun XIAO ; Feng Yu LIANG ; Xia Bi KE ; Juan SU ; Hong XIAO ; Tao WANG ; Min ZOU ; Jian Hong LI ; Wen Chang KE
Biomedical and Environmental Sciences 2024;37(3):278-293
Objective This study aimed to understand the epidemic status and phylogenetic relationships of rotavirus group A(RVA)in the Pearl River Delta region of Guangdong Province,China. Methods This study included individuals aged 28 days-85 years.A total of 706 stool samples from patients with acute gastroenteritis collected between January 2019 and January 2020 were analyzed for 17 causative pathogens,including RVA,using a Gastrointestinal Pathogen Panel,followed by genotyping,virus isolation,and complete sequencing to assess the genetic diversity of RVA. Results The overall RVA infection rate was 14.59%(103/706),with an irregular epidemiological pattern.The proportion of co-infection with RVA and other pathogens was 39.81%(41/103).Acute gastroenteritis is highly prevalent in young children aged 0-1 year,and RVA is the key pathogen circulating in patients 6-10 months of age with diarrhea.G9P[8](58.25%,60/103)was found to be the predominant genotype in the RVA strains,and the 41 RVA-positive strains that were successfully sequenced belonged to three different RVA genotypes in the phylogenetic analysis.Recombination analysis showed that gene reassortment events,selection pressure,codon usage bias,gene polymorphism,and post-translational modifications(PTMs)occurred in the G9P[8]and G3P[8]strains. Conclusion This study provides molecular evidence of RVA prevalence in the Pearl River Delta region of China,further enriching the existing information on its genetics and evolutionary characteristics and suggesting the emergence of genetic diversity.Strengthening the surveillance of genotypic changes and gene reassortment in RVA strains is essential for further research and a better understanding of strain variations for further vaccine development.
2.Celastrol ameliorates atopic dermatitis by modulating Ezrin activation
Hong-Yu JIN ; Dan-Dan WANG ; Xin-Yi SONG ; Ke-Xin XU ; Guang-Hai YAN ; Liang-Chang LI
Chinese Pharmacological Bulletin 2024;40(10):1921-1930
Aim To investigate the effect of Celastrol on the expression of Ezrin in tissues and HaCaT cells of DNCB sensitisation-induced atopic dermatitis(AD)mice.Methods BALB/c mice were taken and ran-domly divided into the control,DNCB group,Celastrol 25 μg,50 μg,75 μg treatment group,and Dex group,with 8 mice in each group;HaCaT cells were induced with TNF-α and treated with 1 μmol·L-1 Celastrol and Ezrin siRNA.The thickness of the skin on the ear and back of mice was measured by a thickness gauge,and the spleen and lymph nodes of mice were taken to observe the changes.HE and toluidine blue staining were used to observe the inflammatory cells and mast cell infiltration in mice.Flow cytometry was used to detect the levels of IL-4 and TNF-α in the lymph nodes of mice,and enzyme-linked immunosorbent was used to determine the levels of IL-4,TNF-α and IgE in serum of mice,and the expression of IL-4,IL-5 and IL-13 in the supernatant of HaCaT cells.Western blot was used to detect the expression of P-Ezrin and Ezrin in skin tissues.Results Celastrol significantly inhibited the swelling of ear and back skin tissues,reduced the de-granulation of inflammatory cells and mast cells,low-ered serum IgE and serum and lymph node levels of IL-4 and TNF-α,and reduced the activation of Ezrin in mice,and the expression of IL-4,IL-5 and IL-13 in the supernatant of HaCaT cells was restored by the treat-ment with Ezrin siRNA.Conclusion Celastrol amel-iorates AD,which may be achieved by modulating Ezrin activation.
3.Efficacy and safety of neoadjuvant chemotherapy combined with PD-1 antibody for esophageal squamous cell carcinoma in the real world.
Pu Yuan WU ; Tao WANG ; Bao Jun CHEN ; Min Ke SHI ; Bin HUANG ; Nan Die WU ; Liang QI ; Xiao Feng CHANG ; Li Feng WANG ; Bao Rui LIU ; Wei REN
Chinese Journal of Oncology 2023;45(2):170-174
Objective: To evaluate the efficacy and safety of neoadjuvant chemotherapy combined with programmed death-1 (PD-1) antibody in operable, borderline or potentially resectable locally advanced esophageal squamous cell carcinoma(ESCC) in the real world. Methods: The study retrospectively analyzed 28 patients with operable or potentially resectable locally advanced ESCC patients treated with preoperative chemotherapy combined with PD-1 inhibitor in Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School from April 2020 to March 2021. According to the clinical TNM staging system of the 8th edition of the American Joint Committee on Cancer, there were 1, 15, 10, 1 and 1 case of stage Ⅱ, Ⅲ, ⅣA, ⅣB and unknown stage respectively. The treatment was two cycle of dual drug chemotherapy regimen including taxane plus platinum or fluorouracil combined with PD-1 antibody followed by tumor response assessment and surgery if the patient was eligible for resection. Results: Of the 28 patients, 1, 2, 3 and 4 cycles of chemotherapy combined with PD-1 antibody treatment completed in 1, 21, 5, and 1 patient, respectively. Objective response rate (ORR) was 71.4% (20/28), and disease control rate (DCR) was 100% (28/28). The incidence of adverse events exceeding grade 3 levels was 21.4% (6/28), including 3 neutropenia, 1 leukopenia, 1 thrombocytopenia and 1 immune hepatitis. There was no treatment-related death. Of the 23 patients underwent surgery, R0 resection rate was 87.0% (20/23), 13 patients had down staged to the T1-2N0M0 I stage, the pCR rate was 17.3% (4/23), and the pCR rate of primary tumor was 21.7% (5/23). Four patients received definitive chemoradiotherapy. One patient rejected surgery and other treatment after achieved PR response. Conclusion: Neoadjuvant chemotherapy combined PD-1 inhibitor is safe and has high efficacy in operable, borderline or potentially resectable locally advanced ESCC, and it is a promising regimen.
Humans
;
Antibodies/therapeutic use*
;
Antineoplastic Combined Chemotherapy Protocols
;
Carcinoma, Squamous Cell/surgery*
;
Cisplatin
;
Esophageal Neoplasms/surgery*
;
Esophageal Squamous Cell Carcinoma/drug therapy*
;
Immune Checkpoint Inhibitors/therapeutic use*
;
Neoadjuvant Therapy
;
Programmed Cell Death 1 Receptor/therapeutic use*
;
Retrospective Studies
;
Treatment Outcome
4.Glutamate-releasing BEST1 channel is a new target for neuroprotection against ischemic stroke with wide time window.
Shuai XIONG ; Hui XIAO ; Meng SUN ; Yunjie LIU ; Ling GAO ; Ke XU ; Haiying LIANG ; Nan JIANG ; Yuhui LIN ; Lei CHANG ; Haiyin WU ; Dongya ZHU ; Chunxia LUO
Acta Pharmaceutica Sinica B 2023;13(7):3008-3026
Many efforts have been made to understand excitotoxicity and develop neuroprotectants for the therapy of ischemic stroke. The narrow treatment time window is still to be solved. Given that the ischemic core expanded over days, treatment with an extended time window is anticipated. Bestrophin 1 (BEST1) belongs to a bestrophin family of calcium-activated chloride channels. We revealed an increase in neuronal BEST1 expression and function within the peri-infarct from 8 to 48 h after ischemic stroke in mice. Interfering the protein expression or inhibiting the channel function of BEST1 by genetic manipulation displayed neuroprotective effects and improved motor functional deficits. Using electrophysiological recordings, we demonstrated that extrasynaptic glutamate release through BEST1 channel resulted in delayed excitotoxicity. Finally, we confirmed the therapeutic efficacy of pharmacological inhibition of BEST1 during 6-72 h post-ischemia in rodents. This delayed treatment prevented the expansion of infarct volume and the exacerbation of neurological functions. Our study identifies the glutamate-releasing BEST1 channel as a potential therapeutic target against ischemic stroke with a wide time window.
5.Genomic Epidemiology of Imported Cases of COVID-19 in Guangdong Province, China, October 2020 - May 2021.
Dan LIANG ; Tao WANG ; Jiao Jiao LI ; Da Wei GUAN ; Guan Ting ZHANG ; Yu Feng LIANG ; An An LI ; Wen Shan HONG ; Li WANG ; Meng Lin CHEN ; Xiao Ling DENG ; Feng Juan CHEN ; Xing Fei PAN ; Hong Ling JIA ; Chun Liang LEI ; Chang Wen KE
Biomedical and Environmental Sciences 2022;35(5):393-401
Objective:
The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been engendering enormous hazards to the world. We obtained the complete genome sequences of SARS-CoV-2 from imported cases admitted to the Guangzhou Eighth People's Hospital, which was appointed by the Guangdong provincial government to treat coronavirus disease 2019 (COVID-19). The SARS-CoV-2 diversity was analyzed, and the mutation characteristics, time, and regional trend of variant emergence were evaluated.
Methods:
In total, 177 throat swab samples were obtained from COVID-19 patients (from October 2020 to May 2021). High-throughput sequencing technology was used to detect the viral sequences of patients infected with SARS-CoV-2. Phylogenetic and molecular evolutionary analyses were used to evaluate the mutation characteristics and the time and regional trends of variants.
Results:
We observed that the imported cases mainly occurred after January 2021, peaking in May 2021, with the highest proportion observed from cases originating from the United States. The main lineages were found in Europe, Africa, and North America, and B.1.1.7 and B.1.351 were the two major sublineages. Sublineage B.1.618 was the Asian lineage (Indian) found in this study, and B.1.1.228 was not included in the lineage list of the Pangolin web. A reasonably high homology was observed among all samples. The total frequency of mutations showed that the open reading frame 1a (ORF1a) protein had the highest mutation density at the nucleotide level, and the D614G mutation in the spike protein was the commonest at the amino acid level. Most importantly, we identified some amino acid mutations in positions S, ORF7b, and ORF9b, and they have neither been reported on the Global Initiative of Sharing All Influenza Data nor published in PubMed among all missense mutations.
Conclusion
These results suggested the diversity of lineages and sublineages and the high homology at the amino acid level among imported cases infected with SARS-CoV-2 in Guangdong Province, China.
Amino Acids
;
COVID-19/epidemiology*
;
Genomics
;
Humans
;
Mutation
;
Phylogeny
;
SARS-CoV-2/genetics*
6.History and present situation of seromuscular flap anastomosis in proximal gastrectomy.
Lin Guang FAN ; Ke Chang ZHANG ; Peng CUI ; Liang ZONG ; Wei WEI ; Jie WANG ; Qi Sheng CHENG ; Jin Jie ZHANG ; Yong LIU ; Yin Hao YANG ; Mao Jie ZHANG ; Wen Qing HU
Chinese Journal of Gastrointestinal Surgery 2022;25(5):466-470
With the increasing detection rate of early upper gastric cancer and adenocarcinoma of esophagogastric junction, the safety of proximal gastrectomy with clear indications has been verified, and function-preserving proximal gastrectomy has been widely used. However, proximal gastrectomy destructs the normal anatomical structure of esophagogastric junction, resulting in severe postoperative gastroesophageal reflux symptoms and seriously affecting the quality of life. Among various anti-reflux surgery methods, reconstruction of "cardiac valve" has always been the focus of relevant scholars because its similarity with the mechanism of normal anti-reflux. After years of development, evolution and optimization, the designed seromuscular flap anastomosis includes tunnel muscle flap anastomosis, Hatafuku valvuloplasty, single muscle flap anastomosis and double muscle flap anastomosis. The double muscle flap anastomosis has become a research hotspot because it shows good anti-reflux effect in clinical application. This paper reviews the history, research status and hot issues of seromuscular flap anastomosis of esophageal remnant stomach at home and abroad.
Anastomosis, Surgical/methods*
;
Esophagogastric Junction/surgery*
;
Gastrectomy/methods*
;
Gastroesophageal Reflux/surgery*
;
Humans
;
Quality of Life
;
Stomach Neoplasms/surgery*
7. The Crystal Structure and Molecular Docking of CYP76AH3 in the Tanshinone Biosynthesis Pathway
Zhang-Xin CHEN ; Ke HE ; Chao SHI ; Li-Xin HUANG ; Zhen-Zhan CHANG ; Cheng-Liang XIAO
Chinese Journal of Biochemistry and Molecular Biology 2022;38(4):488-494
Salvia miltiorrhiza is widely used in the treatment of the angina pectoris, coronary heart disease and myocardial infarction. CYP76AH3 is the key P450 enzyme, locating at the branch point of the tanshinone synthesis pathway. The crystal structural study and key amino acid analysis are of great significance for synthetic biology study on tanshinone. But it is always a challenge for scientists to carry out protein purification, crystallization and crystal structural studies on transmembrane type Ⅱ P450 enzymes. In this study, the prokaryotic expression plasmid was generated, and the high-purity target protein was purified. CYP76AH3 was successfully crystallized, and the crystal structure was solved.After docking range was determined by Cavityplus analysis, molecular docking with Discovery Studio was conducted. The docking result indicated that Gly298 and Asp294 had hydrogen bond interaction with the substrate, while Phe479, Leu367 and Leu293 had hydrophobic interaction with the substrate.In addition, the effect of mutations at the key amino acids on the protein structure stability was predicted throung point mutation simulation. This study would provide a target for protein engineering of CYP76AH3 and lay a foundation for the study of synthesis biology on tanshinones.
8.Kinetic Characteristics of Neutralizing Antibody Responses Vary among Patients with COVID-19.
Ling Hua LI ; Hong Wei TU ; Dan LIANG ; Chun Yan WEN ; An An LI ; Wei Yin LIN ; Ke Qi HU ; Wen Shan HONG ; Yue Ping LI ; Juan SU ; San Tao ZHAO ; Wei LI ; Run Yu YUAN ; Ping Ping ZHOU ; Feng Yu HU ; Xiao Ping TANG ; Chang Wen KE ; Bi Xia KE ; Wei Ping CAI
Biomedical and Environmental Sciences 2021;34(12):976-983
Objective:
The coronavirus disease 2019 (COVID-19) pandemic continues to present a major challenge to public health. Vaccine development requires an understanding of the kinetics of neutralizing antibody (NAb) responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Methods:
In total, 605 serum samples from 125 COVID-19 patients (from January 1 to March 14, 2020) varying in age, sex, severity of symptoms, and presence of underlying diseases were collected, and antibody titers were measured using a micro-neutralization assay with wild-type SARS-CoV-2.
Results:
NAbs were detectable approximately 10 days post-onset (dpo) of symptoms and peaked at approximately 20 dpo. The NAb levels were slightly higher in young males and severe cases, while no significant difference was observed for the other classifications. In follow-up cases, the NAb titer had increased or stabilized in 18 cases, whereas it had decreased in 26 cases, and in one case NAbs were undetectable at the end of our observation. Although a decreasing trend in NAb titer was observed in many cases, the NAb level was generally still protective.
Conclusion
We demonstrated that NAb levels vary among all categories of COVID-19 patients. Long-term studies are needed to determine the longevity and protective efficiency of NAbs induced by SARS-CoV-2.
Adult
;
Aged
;
Aged, 80 and over
;
Antibodies, Neutralizing/immunology*
;
Antibodies, Viral/immunology*
;
COVID-19/immunology*
;
Female
;
Humans
;
Kinetics
;
Male
;
Middle Aged
;
Neutralization Tests
;
SARS-CoV-2
9.Comparison of segmentectomy versus lobectomy for ≤2 cm lung adenocarcinoma with micropapillary and solid subtype negative by intraoperative frozen sections: A multi-center randomized controlled trial
Chang CHEN ; Yuming ZHU ; Gening JIANG ; Haifeng WANG ; Dong XIE ; Hang SU ; Long XU ; Deping ZHAO ; Liang DUAN ; Boxiong XIE ; Chunyan WU ; Likun HOU ; Huikang XIE ; Junqiang FAN ; Xuedong ZHANG ; Weirong SHI ; Honggang KE ; Lei ZHANG ; Hao WANG ; Xuefei HU ; Qiankun CHEN ; Lei JIANG ; Wenxin HE ; Yiming ZHOU ; Xiong QIN ; Xiaogang ZHAO ; Hongcheng LIU ; Peng ZHANG ; Yang YANG ; Ming LIU ; Hui ZHENG
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2021;28(11):1292-1298
Objective To compare the clinical effects of segmentectomy and lobectomy for ≤2 cm lung adenocarcinoma with micropapillary and solid subtype negative by intraoperative frozen sections. Methods The patients with adenocarcinoma who received segmentectomy or lobectomy in multicenter from June 2020 to March 2021 were included. They were divided into two groups according to a random number table, including a segmentectomy group (n=119, 44 males and 75 females with an average age of 56.6±8.9 years) and a lobectomy group (n=115, 43 males and 72 females with an average of 56.2±9.5 years). The clinical data of the patients were analyzed. Results There was no significant difference in the baseline data between the two groups (P>0.05). No perioperative death was found. There was no statistical difference in the operation time (111.2±30.0 min vs. 107.3±34.3 min), blood loss (54.2±83.5 mL vs. 40.0±16.4 mL), drainage duration (2.8±0.6 d vs. 2.6±0.6 d), hospital stay time (3.9±2.3 d vs. 3.7±1.1 d) or pathology staging (P>0.05) between the two groups. The postoperative pulmonary function analysis revealed that the mean decreased values of forced vital capacity and forced expiratory volume in one second percent predicted in the segmentectomy group were significantly better than those in the lobectomy group (0.2±0.3 L vs. 0.4±0.3 L, P=0.005; 0.3%±8.1% vs. 2.9%±7.4%, P=0.041). Conclusion Segmentectomy is effective in protecting lungs function, which is expected to improve life quality of patients.
10.Current status of research on standardized management of specimens after radical gastrectomy for gastric cancer.
Yong LIU ; Ke Chang ZHANG ; Lin Guang FAN ; Jie WANG ; Qi Sheng CHENG ; Dong Yang SONG ; Peng CUI ; Liang ZONG ; Wen Qing HU
Chinese Journal of Gastrointestinal Surgery 2021;24(5):463-466
The quality control and standardization of procedures in radical gastrectomy for gastric cancer, especially the standardized processing of specimens after radical gastrectomy for gastric cancer, is very important. It is not only the basis of accurate pathological staging, but also the evidence of surgical quality and the original data of clinical research, which plays a pivotal role. The examination and classification of lymph nodes, specimens processing records, and data uploading and archiving after radical gastrectomy for gastric cancer are indispensable. It is necessary for surgeons to participate in the processing of surgical specimens. This article will combine the current research status and progress at home and abroad to review the standardized processing of specimens after radical gastrectomy for gastric cancer.
Gastrectomy
;
Humans
;
Lymph Node Excision
;
Lymphatic Metastasis
;
Neoplasm Staging
;
Stomach Neoplasms/surgery*


Result Analysis
Print
Save
E-mail